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Introduction
The interaction between acute myeloid leukemia (AML) cells and the bone marrow (BM) microenvironment has been postulated to be important for resistance to chemotherapy and disease relapse in AML. 1 The chemokine receptor CXCR4 and its ligand, stromal cell-derived factor-1 alpha (SDF-1α, CXCL12), are key mediators of this interaction. SDF-1α is produced in the BM microenvironment, activates CXCR4 on leukemic cells, facilitates leukemia cell trafficking and homing in the BM microenvironment, and keeps leukemic cells in close contact with the stromal cells and extracellular matrix that constitutively generate growth-promoting and anti-apoptotic signals. 2 Indeed, high CXCR4 expression on AML blasts is known to be associated with poor prognosis. 3, 4 Our group and others have tested small-molecule inhibitors against CXCR4: AMD3100 (Plerixafor), approved by the U.S. Food and Drug Administration, and its analogue AMD3465. These agents disrupted the SDF-1α/CXCR4 axis and enhanced the anti-leukemic effects of chemotherapy, markedly reducing leukemic burden and prolonging overall survival in xenograft models. 5, 6 Disruption of the SDF-1α/CXCR4 axis by CXCR4 antagonists is therefore an attractive investigational therapeutic approach for AML and is being tested in clinical trials. A phase I/II study recently reported that adding AMD3100 to cytotoxic chemotherapy increased response rates in patients with relapsed AML. 1 However, the mobilization of leukemic blasts induced by AMD3100 is transient, and cell counts return to baseline levels within 12 hours, 5 likely because of incomplete inhibition of the SDF-1α/CXCR4 axis and the short in vivo half-life (3-5 hours) of AMD3100. 7 Furthermore, AMD3100 and AMD3465 did not show anti-leukemic effects as single agents in vivo, 5, 6 although they did have inhibitory effects on multiple cancers of non-hematologic origin. [8] [9] [10] [11] [12] [13] [14] [15] [16] LY2510924 is a novel and potent selective peptide antagonist of CXCR4. 17 A recent phase I study in advanced cancers revealed good tolerability with mostly grade 1/2 adverse events, favorable pharmacokinetics, and target engagement as indicated by dose-dependent increases in CD34 + cell mobilization. 18 Here, we report preclinical studies using LY2510924 to disrupt the SDF-1α/CXCR4
axis in AML cells in vitro and in vivo.
For personal use only. on . by guest www.bloodjournal.org From
Materials and methods
Please refer to Supplemental Methods for detailed descriptions of the methods and reagents used.
Cell lines, primary samples, and cultures
Human AML cell lines OCI-AML3, U937, and MOLM-13 (Supplemental Table S1 ), were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum (Gemini Bio-Products, West Sacramento, CA) and 1% penicillin-streptomycin (Gibco Laboratories, Grand Island, NY). Cells were harvested during the log phase of growth and seeded at a density of 0. 
Flow cytometry
The expression of surface CXCR4 protein was analyzed by using a Gallios flow cytometer (Beckman Coulter, Brea, CA). Harvested cells were stained with antibodies against CXCR4-allophycocyanin (APC; 12G5) and CXCR4-phycoerythrin (1D9). All antibodies were purchased from BD Biosciences (San Jose, CA). The appropriate isotype-matched antibody was used as a negative control. In vivo leukemic cells were isolated by further staining of samples from mice with human CD45-APC for OCI-AML3/Luc/mCherry cells, CD45-PerCP-Cy5.5 for OCI-AML3/Luc/GFP cells, 19 and CD34-PECy7 and CD45-APC-H7 for primary AML cells. Flow cytometric data were analyzed with FlowJo (Version vX.0.6) software.
Chemotaxis studies
OCI-AML3 cells and primary samples from AML patients (Supplemental Table S2 and supplemental Figure S1 ) were subjected to chemotaxis studies in 6.5-mm-diameter Transwell culture inserts (Costar, Corning, NY) with a pore size of 5 µm. All experiments were conducted in triplicate, and results are 
Western blot analysis
Cell lysates were separated on 12% polyacrylamide gels, transferred to nitrocellulose membranes, stained with the appropriate antibodies and infrared secondary antibodies (LI-COR Biosciences, Lincoln, NE), and quantified by the Odyssey imaging system (LI-COR Biosciences). Antibodies used were rabbit anti-human phospho-AKT (Ser473), AKT, and phospho-GSK-3β (Ser9), mouse antihuman phospho-p44/p42 MAPK (Erk1/2)(Thr202/Tyr204) (all four, Cell Signaling Technology, Beverly, MA), and mouse anti-human active-β-catenin (Millipore, Temecula, CA), Bcl-2 (Dako North America, Inc., Carpenteria, CA), ERK2 and GSK-3β (Santa Cruz Biotechnology, Santa Cruz, CA).
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and β -tubulin was used as the loading control.
Co-culture with stromal cells

OCI-AML3 cells were co-cultured with MS-5 or human mesenchymal stromal cells (hMSC). After 72
hours of incubation at 37°C in a humidified atmosphere containing 5% CO 2 , co-cultured cells were harvested, and viable and apoptotic OCI-AML3 cells were quantified by flow cytometry.
AML mouse models
NOD/SCID/IL-2rγnull (NSG) mice were used for in vivo xenograft experiments. Mice were injected with OCI-AML3 cells labeled with Luc/mCherry or Luc/GFP 19 or primary AML cells to establish AML. All animal experiments were done in accordance with a protocol approved by the Institutional Animal Care and Use Committee at The University of Texas MD Anderson Cancer Center.
Flow cytometry for detection of intracellular phospho-proteins
Changes in AKT and ERK phosphorylation were measured in the xenograft mouse model of primary AML by multi-parametric phospho-flow cytometry in dual positive cells (human CD34 and CD45) recovered from the BM and spleen of a representative mouse from each treatment group on day 48 after transplantation.
Gene expression profiling
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Xenotransplanted OCI-AML3 cells were harvested and isolated on days 41-43 and preserved in RNAlater solution. Total RNA was extracted, amplified, and labeled through two rounds of in vitro transcription and then hybridized to Illumina HT12 version 4 human whole-genome arrays as described previously. 20 Gene expression data were submitted to Gene Expression Omnibus as GSE64623.
Statistical analysis
In general, results are expressed as the mean ± standard deviation (SD) for triplicate experiments or mean ± standard error of the mean (SEM) for triplicate independent experiments. The Student paired 
Results
LY2510924 rapidly and durably blocks surface CXCR4 and inhibits SDF-1α-induced chemotaxis and prosurvival signals of leukemic cells
To determine the effects of CXCR4 blockade by LY2510294, we used AML cell lines OCI-AML3, U937, and MOLM-13, which express high levels of CXCR4 on their cell surface. Flow cytometry results showed that LY2510924 inhibited binding of anti-CXCR4 antibody 12G5 to surface CXCR4 in a concentration-dependent fashion in AML cells ( Figure 1A and 1B, Supplemental Figure S2 ).
LY2510924 was much more potent than AMD3100 in causing CXCR4 blockade. CXCR4 occupancy by LY2510924 in OCI-AML3 cells started as early as 1 minute after treatment ( Figure 1C ) and continued for as long as 72 hours at 10 nM, in contrast to the short duration of blockade by AMD3100 ( Figure 1D ). Both LY2510924 and AMD3100 induced moderate upregulation of cell surface CXCR4 as measured by the 1D9 antibody, which binds to a different CXCR4 epitope (Supplemental Figure   S3 ), suggesting the accumulation of CXCR4 on cell surface due to inhibition of SDF-1α-induced CXCR4 internalization.
1 SDF-1α-induced migration of OCI-AML3 ( Figure 1E ) and primary AML cells ( Figure 1F p=0.013). Proliferation was inhibited by LY2510924 (day 4, p=0.003; day 6, p=0.013; day 8, p=0.001; Figure 2A) , to the same level in the presence or absence of SDF-1α; the effect of LY2510924 alone, as compared to control, was significant at days 4 (p=0.005), 6 (p<0.001), and 8 (p=0.002; Figure 2A ).
However, LY2510924 did not induce AML cell death in vitro (Supplemental Figure S4 ). Figure 3E ). This antileukemia effect translated into significant prolongation of survival in LY2510924-treated mice (median survival, 40 days vs. 26 days; p<0.001; Figure 3F ).
LY2510924 inhibits progression of primary AML cells in xenograft models
To confirm the anti-leukemia efficacy of LY2510924, we injected primary AML cells derived from patient with complex karyotype and high CXCR4 surface expression (Supplemental Figure S6 ) into non-irradiated NSG mice. Mice were divided into two groups after engraftment was documented in peripheral blood, and one group began treatment with LY2510924 on day 25. The proportion of circulating leukemic cells was measured in five representative mice from each group after the first LY2510924 administration. Circulating leukemia cells were significantly increased by LY2510924 3 hours after treatment compared to controls (2.1±0.2-vs. 1.4±0.1-fold increase over baseline, p=0.008) and were increased by even more 24 hours after treatment (2.7±0.4-vs. 1.0±0.1-fold increase over baseline, p=0.008; Figure 4A and Supplemental Figure S6 ). Flow cytometry showed sustained inhibition of CXCR4 staining by 12G5 at 3 and 24 hours after the first LY2510924 injection ( Figure   4B ), and significant blockade after five daily treatments compared to controls (2.7±0.1-vs 10.2±1.9-fold increase over isotype, p=0.017; Figure 4C ).
On day 45, after 3 weeks of daily LY2510924 treatment, three mice were sacrificed in each group, and flow cytometry of leukemic cells in their blood, BM, and spleens revealed significant blockade of CXCR4 12G5 staining by LY2510924 ( Figure 4D ). This analysis also demonstrated that mice treated with LY2510924 had lower leukemic cell burden in blood (50.5%±2.4% vs. 86.1%±2.9%, p<0.001), BM (72.1%±3.6% vs. 89.7%±1.9%, p=0.012), and spleen (19.6%±0.6% vs. 60.1%±0.7%, p<0.001; Figure 4E ). Multi-parametric phospho-flow cytometry showed decreases in AKT and/or ERK phosphorylation in leukemic cells recovered from the spleen and BM of a LY2510924-treated mouse on day 48 ( Figure 4F ), which was consistent with our in vitro data ( Figures 1G and 1H ). These anti-1 0 leukemia effects of LY2510924 alone resulted in significant prolongation of survival (median survival, 56 days vs. 44 days; overall, p<0.001, Figure 4G ).
Combination with chemotherapy enhances LY2510924 anti-leukemia effects in OCI-AML3 xenograft models
To further explore the anti-leukemia efficacy of LY2510924 in combination with chemotherapy in vivo, we injected OCI-AML3/Luc/GFP cells 19 into non-irradiated NSG mice. Mobilization studies were carried out in two groups of six mice each; in mice given their first LY2510924 injection on day 25, prolonged mobilization of leukemic cells into the circulation by LY2510924 was confirmed To elucidate the molecular effects of inhibiting CXCR4-mediated signaling in AML cells in vivo, we again used the OCI-AML3/Luc/GFP xenograft model. Engraftment, assessed as sufficient involvement of the blood by leukemic cells (3.3%±1.1%), was reached in eight mice on day 40.
Groups of these mice began daily treatment with LY2510924 on that day, and were sacrificed 24 hours (day 41, after one treatment; n=3) or 72 hours (day 43, after three treatments; n=2) later. Three untreated mice were sacrificed on day 42 as controls. Leukemic cells were isolated from BM, blood, and spleen of all of these by fluorescence-activated cell sorting (FACS) by human CD45 and GFP (Supplemental Figure S8) . Samples from each site and time point were also analyzed for CXCR4 occupancy using flow cytometry with antibody 12G5. CXCR4 blockade by LY2510924 was delayed in BM compared to that in blood and spleen ( Figure 6A ), but unoccupied CXCR4 in BM was decreased to a similar level as measured in blood and spleen at 72 hours, suggesting that repeated doses are needed to affect leukemic cells in BM.
Genome-wide gene expression profiling (GEP) was performed on 24 samples of leukemic cells from various sites and treatment time points. When profiles of all samples were compared to the average profile of untreated BM, by displaying fold-change values for altered genes in a subtracted and clustered heat map ( Figure 6B ), there was remarkable similarity between the changes detected in leukemic cells localized in a site other than BM (i.e., blood or spleen) and changes caused by treatment with LY2510924. Furthermore, changes were greatest in samples from non-BM locations in treated mice, especially at 72 hours. GEP findings were also consistent with the finding of less CXCR4 blockade in BM at 24 hours ( Figure 6A ): at 24 hours, BM samples were relatively unaffected, whereas moderate changes were noted in all three spleen samples and one of three blood samples, and marked changes were noted in two of three blood samples. Assuming that SDF-1α/CXCR4 signaling is strongest in the BM, the consistency of GEP changes caused by either non-BM localization or LY2510924 treatment, and the enhancement and extension of these changes by the combination of these factors, further accentuated by treatment duration, suggest that LY2510924 is indeed a specific inhibitor of SDF-1α/CXCR4 signaling.
For
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Biological effects of SDF-1α/CXCR4 signaling in vivo involve differentiation and proliferation of AML GEP data were also analyzed to investigate the biological effects of SDF-1α/CXCR4 signaling in leukemic cells. To utilize GEP data for all 24 samples, we relied on the impression from Figure 6B that there was qualitative similarity in the effects of non-BM localization and/or LY2510924 treatment, assigning to each sample a score for the presumed relative degree of loss of SDF-1α/CXCR4
signaling (see Supplemental Methods). Genes were then assessed for correlation between their expression levels and this score in all samples, using the Pearson correlation r value in a metric that also considered the variance of gene expression values (Supplemental Data File S1). Genes with the highest positive values of the correlation metric, i.e., those upregulated by loss of SDF-1α/CXCR4 signaling, were predominantly associated with myelomonocytic differentiation, including CD14, TREM1, CD300a, LILRA5, LILRB3, and S100A12 ( Figure 6C ). This suggests that although OCI-AML3 is a cell line, it undergoes myelomonocytic differentiation in vivo, regulated by SDF-1α/CXCR4 signaling. Genes with the most negative values of the correlation metric, i.e., those downregulated by loss of SDF-1α/CXCR4 signaling, include MS4A3, a hematopoietic cell cycle regulator that is downregulated during differentiation. 22 The effect of SDF-1α/CXCR4 inhibition on myeloid differentiation was supported by immunohistochemical analysis of tissues from OCI-AML3-Luc-mCherry xenograft model demonstrating increases of CD11c positive cells in LY2510924-treated mouse compared to an untreated mouse (BM, 60% vs. 23%; Liver, 45% vs. 18%; Figure 7 ). Tissues from primary AML xenograft model also showed similar findings (Supplemental Figure S9 ). Other notable negatively correlated genes include negative regulators of apoptosis (BCL2 and RPL23), and genes involved in proliferation (e.g., MAD2L1, BUB1, and NCAPG2; Figure 6C ). We confirmed decreased Bcl-2 levels by Western blot analysis ( Figure 6D ).
Gene set enrichment analysis was performed, based on ranking genes by the correlation metric, to investigate further the biological effects of these changes. Among multiple gene sets that were significantly enriched (Supplemental Data File S2), positive enrichment of the gene set SDF-1α-induced PI3K/AKT and MAPK prosurvival signaling, consistent with our previous report on AMD3465.
6 PI3K/AKT and MAPK pathways are key signaling pathways promoting leukemic cell survival 31,32 and are known to be linked to the SDF-1α/CXCR4 axis. 33 We have reported the potential of both stromal cells and SDF-1α to activate PI3K/AKT and MAPK prosurvival pathways. 6 ,34 There may be other effects and signaling pathways activated in AML cells by stromal cells; although these need to be identified, especially for rational combination strategies, they may be indirectly abrogated by the mobilizing effect of SDF-1α/CXCR4 inhibition. Our microarray results also suggest that inhibiting SDF-1α/CXCR4 signaling may affect Wnt/β-catenin pathway, and Western blot analysis
showed that the attenuation of PI3K/ATK in vivo by LY2510924 results in GSK-3β kinase activation by dephosphorylation, which decreases activated β -catenin levels, consistent with data in peripheral nerve sheath tumors. 16 There may be additional signaling pathways and effectors of AKT and β -catenin that require further investigation.
Previous preclinical and clinical studies of SDF-1α/CXCR4 inhibition in AML have shown both promise and limitations. Small-molecule CXCR4 antagonists, such as AMD3100 or AMD3465, did not show anti-leukemia effects as monotherapy in certain studies. 5, 6 While this limitation may have been isolated to these particular drugs, or to the way in which they were used, our results suggest that this limitation is overcome when the SDF-1α/CXCR4 axis is inhibited more effectively, as by LY2510924. Previous studies used CXCR4 antagonists for only very short periods (less than 2 days), or with every-other-day administration, and focused on their effectiveness as chemosensitizers. In line with our results, two reports demonstrated monotherapeutic anti-leukemic effects in preclinical models for CXCR4 antagonism by a monoclonal antibody, MDX-1338, 35 or a peptide inhibitor, TN140. 27 MDX-1338 (given five times for 14 days) inhibited growth of the acute promyelocytic leukemia cell line HL60, 35 and TN140 (given daily by osmotic pump for 7 days) reduced leukemic cell numbers in the BM and prolonged survival in primary AML xenograft models. 27 In both studies, AMD3100 had no effect. In future clinical trials with CXCR4 antagonists, the use of more potent agents and extended treatment duration may be essential to fully disrupt the SDF-1α/CXCR4 axis and Utilization of CXCR4 antagonists with chemotherapy might raise concerns about increased toxicity to normal hematopoiesis. However, our in vivo data ( Figure 5E ) suggested that the toxicity of LY2510924 plus chemotherapy was similar to that of chemotherapy alone. Importantly, recent clinical studies with novel potent CXCR4 antagonists ulocuplumab and BL-8040 demonstrated lack of additive myelosuppression when combined with chemotherapy.
37,38
In conclusion, our study shows that LY2510924 at nanomolar concentrations rapidly and durably disrupts the SDF-1α/CXCR4 axis in AML cells and has greater anti-leukemia efficacy than AMD3100. For (G) or U937 (H) cells in RPMI medium containing 0.5% bovine serum albumin were or were not pretreated with 1 µM LY2510924 for 1 hour and were exposed to 100 ng/mL SDF-1α for 10 minutes.
Phosphorylation of AKT and ERK was detected by Western blot analysis, and the intensity of the bands was quantified by densitometry and displayed as the ratio of phosphorylated protein to control phospho-protein. GAPDH was used as a loading control. All results are expressed as the mean ± SD, with the exception of (F), expressed as the mean ± SEM. For personal use only. on July 15, 2017. by guest www.bloodjournal.org From
